Study | Country | Study period | Cost component | Population | Sample size | Mean annual cost per patient (2020 USD) | GDP per capita (2020 USD) | Proportion of GDP per capita (%) |
---|---|---|---|---|---|---|---|---|
Direct Costs | ||||||||
Collard [2] | US | 2001–2008 | Total direct | IPF | 9286 | 32,834 | 58,160 | 56 |
Collard [40] | US | 2000–2011 | Total direct | IPF | 7855 | 24,198 | 57,395 | 42 |
Mortimer [41] | US | 2008–2014 | Total direct | IPF | 4716 | 23,773 | 60,183 | 40 |
Raimundo [42] | US | 2009–2011 | Total direct | IPF | 3619 | 70,051 | 57,395 | 122 |
Corral [33] | US | 2014–2018 | Total direct | IPF | 1455 | 116,927 | 64,999 | 180 |
Kalluri [34] | Canada | 2012–2018 | Total direct | IPF | 2768 | 49,251 | 47,879 | 103 |
Tarride [11] | Canada | 2006–2011 | Total direct | IPF | 8683 | 10,991 | 60,088 | 18 |
Kim [43] | Korea | 2009–2013 | Total direct | IPF | 18,006 | 1,824 | 30,200 | 6 |
Hilberg [19] | Denmark | 2003–2009 | Total direct | IPF | 120 | 30,513 | 70,167 | 43 |
Olson [44] | US | 2014–2016 | Total direct | Non-IPF PF-ILD | 373 | 85,589 | 62,567 | 137 |
Frank [45] | Germany | 2010–2013 | Total direct | IIP | 14,453 | 18,196 | 51,437 | 35 |
Morrisroe [46] | Australia | 2008–2015 | Total direct | SSc-ILD | 335 | 8,473 | 61,975 | 14 |
Gayle [47] | England | 2005–2016 | Total direct | SSc-ILD | 127 | 10,398* | 44,264 | 23 |
Fisher [48] | US | 2003–2014 | Total direct | SSc-ILD | 219 | 42,878 | 60,183 | 71 |
Zhou [20] | US | 2005–2015 | Total direct | SSc-ILD | 479 | 39,560 | 62,092 | 64 |
Raimundo [49] | US | 2004–2013 | Total direct | RA-ILD | 11,845 | 38,907 | 59,001 | 66 |
Indirect Costs | ||||||||
Algamdi [16] | Canada | 2015–2017 | Productivity loss | Fibrotic ILD | 148 | 9,313 | 47,650 | 20 |
Algamdi [17] | Canada | 2015–2017 | Productivity loss | CTD-ILD | 113 | 10,902 | 47,650 | 23 |
Zhou [20] | US | 2005–2015 | Productivity loss | SSc-ILD | 479 | 7,149 | 62,092 | 12 |
Hilberg [19] | Denmark | 2003–2009 | Income loss | IPF | 120 | 9,901 | 70,167 | 14 |